IPO - AYTU BIOPHARMA, INC

Form Type: 424B4

Filing Date: 2025-06-09

Corporate Action: Ipo

Type: New

Accession Number: 000143774925019761

Filing Summary: Aytu BioPharma, Inc. is offering a firm commitment of 1,366,668 shares of common stock at a public offering price of $1.50 per share and 8,233,332 prefunded warrants to purchase an equivalent number of shares. The prefunded warrants allow holders to purchase shares up to a beneficial ownership cap of 4.99%, which can be increased to 19.99%. The prefunded warrants will be priced slightly lower than the common stock at $1.4999. Existing stockholders, officers, and directors may participate in this offering under the same terms as other investors. The underwriters have the option to purchase an additional 1,440,000 shares within 30 days. As of June 5, 2025, the closing price of the company’s common stock was $1.49. The document outlines significant risk factors associated with the investment, including the company's historical losses, dependence on a few key customers, potential legal challenges, and ongoing discussions for strategic transactions. Additionally, Aytu has completed the divestiture of its Consumer Health business and focuses solely on its pharmaceutical operations aimed at treatments for ADHD and other conditions. The company is also preparing to launch a newly acquired antidepressant product and remains engaged in potential strategic acquisitions. The registration form is filed under the SEC with registration numbers 333-287728 and 333-287825.

Form Type: 8-K

Filing Date: 2025-06-06

Corporate Action: Ipo

Type: New

Accession Number: 000143774925019719

Filing Summary: On June 5, 2025, Aytu BioPharma, Inc. entered into an underwriting agreement with Lake Street Capital Markets, LLC for a public offering of 1,366,668 shares of its common stock at a price of $1.50 per share and 8,233,332 pre-funded warrants at a price of $1.4999 each. The offering is expected to yield net proceeds of approximately $12.9 million, or $14.9 million if the underwriter's option for additional shares is fully exercised. The funds will be used for general corporate purposes, working capital, and to commercialize EXXUATM (gepirone) extended-release tablets. The offering is registered under registration statements that became effective on June 5, 2025, and is expected to close around June 9, 2025. A press release was issued on June 6, 2025, announcing the pricing of the public offering. The Underwriting Agreement contains various representations and customary conditions for closing.

Form Type: S-1MEF

Filing Date: 2025-06-06

Corporate Action: Ipo

Type: New

Accession Number: 000143774925019599

Filing Summary: Aytu BioPharma, Inc. filed a registration statement on Form S-1MEF seeking to register additional securities for their public offering. This filing comes as an amendment to an earlier registration statement (File No. 333-287728), which was declared effective by the SEC on June 5, 2025. The new registration aims to increase the maximum aggregate offering price by $2,760,000, which comprises $2,400,000 in common stock and prefunded warrants to purchase additional common stock, alongside an underwriters' option of $360,000. This filing indicates Aytu BioPharma's intention to proceed with its IPO and expands the offering to include more securities than previously anticipated.

Form Type: S-1/A

Filing Date: 2025-06-05

Corporate Action: Ipo

Type: Update

Accession Number: 000143774925019550

Filing Summary: Aytu BioPharma, Inc. is filing Amendment No. 1 to its Registration Statement on Form S-1 to amend Exhibit 107. The registration involves an offering of securities under the Securities Act. The proposed sale to the public will commence as soon as practicable after the effective date of this registration statement. The registrant is classified as a smaller reporting company and an emerging growth company. This amendment is primarily an exhibits-only filing, indicating that the prospectus itself remains unchanged. The registrant's agent for service and legal representatives are listed, along with their contact information. The document includes a comprehensive list of exhibits filed with the registration statement, including various agreements and amendments, indicating active corporate governance and operational activities.

Form Type: CORRESP

Filing Date: 2025-06-02

Corporate Action: Ipo

Type: New

Accession Number: 000143774925019196

Filing Summary: Aytu BioPharma, Inc. has requested the acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-287728). The company seeks to have the Registration Statement declared effective on June 4, 2025, at 5:00 p.m. Eastern Time, or as soon as practicable thereafter. Upon the declaration of effectiveness, the company requests confirmation of this event through their counsel, Dorsey & Whitney LLP.

Form Type: S-1

Filing Date: 2025-06-02

Corporate Action: Ipo

Type: New

Accession Number: 000143774925019189

Filing Summary: On June 2, 2025, Aytu Biopharma, Inc. filed a registration statement on Form S-1 with the SEC. This registration is intended for an initial public offering of the company's securities. Aytu BioPharma is headquartered in Denver, Colorado, and the filing seeks to raise capital primarily for future business development. The company has specified various financial figures related to its operations and assets, indicating it desires to leverage this public offering to strengthen its capital structure and fund ongoing projects. The registration statement outlines the legal and administrative details necessary for compliance with the Securities Act of 1933, noting that securities will be offered as soon as practicable after the registration's effective date. Key individuals and firms involved in the process have been identified, reflecting the company's active engagement with financial advisors and legal counsel to navigate the IPO process.

Form Type: DRS

Filing Date: 2025-04-28

Corporate Action: Ipo

Type: New

Accession Number: 000143774925013327

Filing Summary: Aytu BioPharma, Inc. has filed a draft registration statement for the proposed public offering of shares of its Common Stock, along with Prefunded Warrants, highlighting its focus on commercializing novel therapeutics. The registration is in light of the company's recent strategic decisions to wind down unprofitable operations and concentrate on its prescription pharmaceutical business. The document details the structure of the offering, including the implications of Prefunded Warrants for purchasers, and outlines the company's intent to utilize proceeds for accelerating its revenue-generating products. Additionally, the registration notes the completion of divesting the Consumer Health business, reflecting a streamlined operational structure. The company plans to continue its efforts in international partnerships and licensing agreements to enhance its product portfolio, further accelerating growth and profitability potential. Furthermore, risks associated with the offering, including market conditions and operational challenges, are clearly detailed, emphasizing the high degree of risk involved in the proposed transaction.